Melanoma News and Research

Latest Melanoma News and Research

iCAD total revenue for Q4 2013 increases 16.8% to $9.1 million

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2013.

19 Feb 2014

Researchers develop method for diagnosis and prognosis of cutaneous melanoma

UPV/EHU researchers have developed a method for the diagnosis and prognosis of cutaneous melanoma, the type of skin cancer with the highest mortality rate.This method will help not only in the more effective early detection of this cancer, but also in the development of more personalised treatments.

19 Feb 2014

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.

19 Feb 2014

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Tel Aviv University researchers won two out of three prestigious melanoma research awards granted this year by The Melanoma Research Alliance and The Saban Family Foundation. The Team Science Awards are the centerpiece of the MRA research fund, which seeks to promote transformational melanoma research for swift clinical implementation.

18 Feb 2014

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

18 Feb 2014

Study affirms new standard for detecting melanoma metastasis to the lymph nodes

Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.

14 Feb 2014

EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014

EKF, announces that its subsidiary company EKF Molecular Diagnostics is exhibiting its ground-breaking PointMan DNA-enrichment tech.

From EKF Diagnostics 11 Feb 2014

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Discovering key elements of immune system T cell biology and applying that knowledge to create a new way to treat cancer has earned Jim Allison, Ph.D., the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.

10 Feb 2014

Study provides extensive review of incidence, risk factors and characteristics of skin cancer in people of color

While people of color have a lower risk of developing skin cancer than Caucasians, they are not immune to the disease. In fact, skin cancer is often diagnosed at a more advanced stage in people of color, which can make it more difficult to treat.

6 Feb 2014

Poll shows only 35% of respondents likely to seek aggressive treatment to cancer

A national poll from the University of Utah's Huntsman Cancer Institute shows 34 percent of respondents would not seek genetic testing to predict their likelihood of developing a hereditary cancer - even if the cost of the testing was not an issue.

6 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

5 Feb 2014

Incidence of skin cancer increased nearly eightfold among middle-aged men and women

A new Mayo Clinic study found that among middle-aged men and women, 40 to 60 years old, the overall incidence of skin cancer increased nearly eightfold between 1970 and 2009, according to a study published in the January issue of Mayo Clinic Proceedings.

5 Feb 2014

Cancer specialist takes efforts to improve survival rates across Europe

Queen's University Belfast's world renowned cancer specialist, Professor Patrick Johnston, whose work has transformed cancer care in Northern Ireland, is now leading efforts to improve survival rates across Europe.

4 Feb 2014

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.

30 Jan 2014

American Cancer Society, SU2C partner to fight against cancer

The American Cancer Society, the largest voluntary health organization in the world dedicated to eliminating cancer, and Stand Up To Cancer, the charitable initiative supporting groundbreaking research aimed at getting new treatments to patients in an accelerated timeframe, announced today an historic collaboration in the fight against cancer, which takes more than 585,000 lives in the U.S. each year and nearly 8 million worldwide.

30 Jan 2014

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

A common surgery for non-melanoma skin cancer, known as Mohs surgery typically achieves excellent results but can be a long process, as the surgeon successively removes the area of concern until the surrounding tissue is free of cancer.

29 Jan 2014

CU receives cooperative agreement to develop technological system to determine effects chemical agents

The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.

29 Jan 2014

Veterans with exposure to Agent Orange may be at higher risk for skin cancer

Vietnam War veterans with prior exposure to the herbicide Agent Orange may be at higher risk for certain types of skin cancer, suggests a report in the February issue of Plastic and Reconstructive Surgery-, the official medical journal of the American Society of Plastic Surgeons (ASPS).

29 Jan 2014

Response of brain tumors from SRS can indicate necessity of follow-up treatments

The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.

28 Jan 2014

Melanoma News and Research

Latest Melanoma News and Research

iCAD total revenue for Q4 2013 increases 16.8% to $9.1 million

Researchers develop method for diagnosis and prognosis of cutaneous melanoma

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Study affirms new standard for detecting melanoma metastasis to the lymph nodes

EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Study provides extensive review of incidence, risk factors and characteristics of skin cancer in people of color

Poll shows only 35% of respondents likely to seek aggressive treatment to cancer

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Incidence of skin cancer increased nearly eightfold among middle-aged men and women

Cancer specialist takes efforts to improve survival rates across Europe

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

American Cancer Society, SU2C partner to fight against cancer

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

CU receives cooperative agreement to develop technological system to determine effects chemical agents

Veterans with exposure to Agent Orange may be at higher risk for skin cancer

Response of brain tumors from SRS can indicate necessity of follow-up treatments

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in